Minimally Invasive Aesthetic Treatment of the Face and Neck Using Combinations of a PCL-Based Collagen Stimulator, PLLA/PLGA Suspension Sutures, and Cross-Linked Hyaluronic Acid.
botulinum toxins
combined modality therapy
dermal fillers
energy-based device
practice guideline
rejuvenation
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
02
2020
accepted:
09
04
2020
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
23
5
2020
Statut:
epublish
Résumé
Combinations of minimally invasive procedures (MIPs) are often used in aesthetic treatments and are increasingly considered as the new standard of care. Three agents with specific properties are available in this perspective: a polycaprolactone (PCL)-based collagen stimulator, a poly-L-lactic acid (PLLA)- and a poly-glycolic acid (PLGA)-based resorbable suspension suture with a 3D-cone technology, and a cross-linked hyaluronic acid (HA). To develop the first practice guidelines on rejuvenation treatment of the face and the neck using combinations of these agents, whether associated or not with other widely used MIPs such as botulinum neurotoxins or energy-based devices. A multi-disciplinary, multi-national board of plastic surgeons and dermatologists convened to develop guidelines using a predefined consensus method. The consensus was defined as ≥83% agreement rate between participants. Practice guidelines and algorithms, describing optimal procedure sequence and spacing, are proposed for the treatment of upper-, mid-, lower-face and neck, combining the PCL collagen stimulator, the PLLA/PLGA suspension sutures, and the cross-linked HA, whether associated or not with other MIPs. These new guidelines provide general support to optimal management strategies. Individual treatment plans should be adapted according to the physician's individual competence and the patient's preferences.
Sections du résumé
BACKGROUND
BACKGROUND
Combinations of minimally invasive procedures (MIPs) are often used in aesthetic treatments and are increasingly considered as the new standard of care. Three agents with specific properties are available in this perspective: a polycaprolactone (PCL)-based collagen stimulator, a poly-L-lactic acid (PLLA)- and a poly-glycolic acid (PLGA)-based resorbable suspension suture with a 3D-cone technology, and a cross-linked hyaluronic acid (HA).
OBJECTIVE
OBJECTIVE
To develop the first practice guidelines on rejuvenation treatment of the face and the neck using combinations of these agents, whether associated or not with other widely used MIPs such as botulinum neurotoxins or energy-based devices.
METHODS
METHODS
A multi-disciplinary, multi-national board of plastic surgeons and dermatologists convened to develop guidelines using a predefined consensus method. The consensus was defined as ≥83% agreement rate between participants.
RESULTS
RESULTS
Practice guidelines and algorithms, describing optimal procedure sequence and spacing, are proposed for the treatment of upper-, mid-, lower-face and neck, combining the PCL collagen stimulator, the PLLA/PLGA suspension sutures, and the cross-linked HA, whether associated or not with other MIPs.
CONCLUSION
CONCLUSIONS
These new guidelines provide general support to optimal management strategies. Individual treatment plans should be adapted according to the physician's individual competence and the patient's preferences.
Identifiants
pubmed: 32440186
doi: 10.2147/CCID.S248280
pii: 248280
pmc: PMC7211299
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
333-344Informations de copyright
© 2020 de Melo et al.
Déclaration de conflit d'intérêts
Dr Francisco de Melo reports personal fees, non-financial support from Sinclair Pharma. Dr Alieksiéi Carrijo, Dr Kyungkook Hong, and Dr Bruno Trumbic report personal fees from Sinclair Pharma. Dr Franco Vercesi was the International Trainer and Key Opinion Leader for Sinclair Pharma. Dr Heidi A Waldorf reports being a honorarium advisory board member for Sinclair Pharma and reports personal fees from Allergan, Endo, Galderma, Merz, Revance, Sinclair Pharma, and Suneva. Dr Sabine Zenker reports personal fees from L’Oréal Paris, Merz, Mesoestetic, Quantificare, and Sinclair Pharma. The authors report no other conflicts of interest in this work.
Références
J Cosmet Dermatol. 2018 Feb;17(1):66-72
pubmed: 29285863
Dermatol Surg. 2016 May;42 Suppl 2:S77-82
pubmed: 27128248
J Cosmet Dermatol. 2018 Dec;17(6):1189-1193
pubmed: 29607627
Clin Cosmet Investig Dermatol. 2017 Oct 30;10:423-429
pubmed: 29133982
J Drugs Dermatol. 2014 Feb;13(2):191-5
pubmed: 24509971
J Appl Biomater. 1994 Summer;5(2):151-7
pubmed: 10147175
J Cosmet Dermatol. 2015 Mar;14(1):27-32
pubmed: 25564797
J Cosmet Laser Ther. 2015 Feb;17(1):49-54
pubmed: 25260050
Aesthet Surg J. 2018 May 15;38(6):654-663
pubmed: 29228145
Dermatol Surg. 2015 Dec;41 Suppl 1:S325-32
pubmed: 26618460
J Clin Aesthet Dermatol. 2015 Oct;8(10 Suppl):S2-7
pubmed: 26587179
Dermatol Surg. 2016 May;42 Suppl 2:S89-93
pubmed: 27128250
Biomaterials. 2006 Mar;27(9):1735-40
pubmed: 16198413
Dermatol Surg. 2013 Mar;39(3 Pt 1):457-63
pubmed: 23350617
J Drugs Dermatol. 2016 Jan;15(1):111-2
pubmed: 26741389
Dermatol Surg. 2016 May;42 Suppl 2:S94-S100
pubmed: 27128251
Dermatol Surg. 2013 Jun;39(6):915-22
pubmed: 23464798
Contraception. 2006 Aug;74(2):141-7
pubmed: 16860052
Curr Opin Ophthalmol. 2006 Oct;17(5):471-9
pubmed: 16932063
J Clin Aesthet Dermatol. 2017 Aug;10(8):16-27
pubmed: 28979659
Plast Reconstr Surg Glob Open. 2017 Dec 28;5(12):e1574
pubmed: 29632761
J Cosmet Laser Ther. 2007 Dec;9(4):249-52
pubmed: 18236245
Clin Plast Surg. 2016 Jul;43(3):449-57
pubmed: 27363759
Ann Dermatol Venereol. 2009 May;136 Suppl 4:S111-8
pubmed: 19576476
Dermatol Surg. 2010 Dec;36 Suppl 4:2121-34
pubmed: 21134044
Dermatol Surg. 2016 May;42 Suppl 2:S168-76
pubmed: 27128245
Plast Reconstr Surg. 2015 Nov;136(5 Suppl):120S-131S
pubmed: 26441092
J Cosmet Laser Ther. 2015 Feb;17(1):46-8
pubmed: 25264587
J Cutan Aesthet Surg. 2009 Jul;2(2):65-71
pubmed: 20808593
Plast Reconstr Surg. 2008 May;121(5 Suppl):5S-30S; quiz 31S-36S
pubmed: 18449026
J Cosmet Dermatol. 2013 Mar;12(1):73-7
pubmed: 23438145
J Cosmet Dermatol. 2018 Jun;17(3):328-332
pubmed: 29314648
Dermatol Surg. 2018 Mar;44(3):421-431
pubmed: 28902030
J Dermatolog Treat. 2018 Jun;29(4):400-404
pubmed: 29098914
Aesthet Surg J. 2016 Mar;36(3):NP122-7
pubmed: 26879301
J Drugs Dermatol. 2017 Jul 1;16(7):661-666
pubmed: 28697217
Plast Reconstr Surg. 1996 Oct;98(5):791-4
pubmed: 8823015
Clin Cosmet Investig Dermatol. 2017 Nov 08;10:431-440
pubmed: 29184426
Plast Reconstr Surg. 2006 Sep 15;118(4):98e-106e
pubmed: 16980841
J Cosmet Dermatol. 2013 Dec;12(4):261-6
pubmed: 24305424
J Drugs Dermatol. 2014 Sep;13(9):1047-52
pubmed: 25226004
J Drugs Dermatol. 2018 Jan 1;17(1):48-54
pubmed: 29320587
Dermatol Surg. 2016 Nov;42(11):1256-1260
pubmed: 27662054
Aesthet Surg J. 2019 Jul 12;39(8):NP343-NP351
pubmed: 30923813
Aesthetic Plast Surg. 2016 Apr;40(2):202-14
pubmed: 26893276
Dermatol Surg. 2016 Oct;42(10):1199-1208
pubmed: 27668925
J Cosmet Laser Ther. 2014 Jan;16(1):37-42
pubmed: 24131095
J Cosmet Laser Ther. 2015 Apr;17(2):99-101
pubmed: 25260139
Aesthetic Plast Surg. 2011 Apr;35(2):248-53
pubmed: 20835823
Dermatoendocrinol. 2012 Jul 1;4(3):308-19
pubmed: 23467476
Skin Res Technol. 2017 Nov;23(4):558-562
pubmed: 28543777
Dermatol Surg. 2016 May;42(5):586-97
pubmed: 27100962
Plast Reconstr Surg. 2016 May;137(5):1410-23
pubmed: 27119917
JAMA Dermatol. 2015 Mar;151(3):271-7
pubmed: 25372511
Dermatol Surg. 2016 May;42 Suppl 2:S177-91
pubmed: 27128246